AI Engines For more Details: Perplexity Kagi Labs You
Heavy Metal Poisoning Treatment: Pentetic acid is used medically as a chelating agent to treat heavy metal poisoning. When administered intravenously, it binds to heavy metals in the bloodstream, forming stable complexes that can be excreted through urine. This helps reduce the concentration of toxic metals in the body and prevents further damage to organs and tissues.
Diagnostic Imaging: Pentetic acid is also used in diagnostic imaging procedures, such as radioisotope imaging scans (e.g., Technetium-99m scans). It is combined with radioactive isotopes (e.g., Technetium-99m) to form radiopharmaceuticals that can be injected into the body. These radiopharmaceuticals help in visualizing organs and tissues during imaging procedures, such as nuclear medicine scans and magnetic resonance imaging (MRI).
Calcium Chelation: In addition to heavy metals, pentetic acid can also chelate calcium ions. This property has been explored in the treatment of conditions such as hypercalcemia (high levels of calcium in the blood) and calcific uremic arteriolopathy (a condition involving calcification of small blood vessels in patients with kidney disease). By binding to excess calcium ions, pentetic acid can help reduce calcium levels in the blood and prevent the formation of calcium deposits in tissues.
Radiation Protection: Pentetic acid has been investigated for its potential role in protecting against the harmful effects of radiation exposure. It is believed to act as a scavenger of free radicals generated by ionizing radiation, thereby reducing oxidative damage to cells and tissues. Research in this area is ongoing, and pentetic acid is not currently widely used for radiation protection in clinical settings.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Bacteroides uniformis | Reduces |
| species | Lacticaseibacillus paracasei | Reduces |
| species | Parabacteroides distasonis | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
| 📓 Direct Citations | 👪👶 Indirect Citations | Taxonomy | Rank | Effect |
|---|---|---|---|---|
| 0 | 1 | Parabacteroides | genus | Decreases |
| 0 | 1 | Bacteroides | genus | Decreases |
| 0 | 1 | Bilophila | genus | Decreases |
| 0 | 1 | Mediterraneibacter | genus | Decreases |
| 0 | 1 | Thomasclavelia | genus | Decreases |
| 0 | 1 | Lacticaseibacillus | genus | Decreases |
| 1 | 0 | Bacteroides xylanisolvens | species | Decreases |
| 1 | 0 | Parabacteroides distasonis | species | Decreases |
| 1 | 0 | Bilophila wadsworthia | species | Decreases |
| 1 | 0 | Lacticaseibacillus paracasei | species | Decreases |
| 1 | 0 | Thomasclavelia ramosa | species | Decreases |
| 1 | 0 | Mediterraneibacter gnavus | species | Decreases |
| 1 | 0 | Bacteroides uniformis | species | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. paracasei | subspecies | Decreases |
| 0 | 1 | Lacticaseibacillus paracasei subsp. tolerans | subspecies | Decreases |
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.3 | 0.3 | |
| Acne | 0.3 | 0.3 | |
| ADHD | 0.5 | 0.5 | |
| Age-Related Macular Degeneration and Glaucoma | 0.4 | -0.4 | |
| Allergic Rhinitis (Hay Fever) | 0.8 | 0.8 | |
| Allergies | 0.5 | 0.3 | 0.67 |
| Allergy to milk products | 0.3 | 0.7 | -1.33 |
| Alopecia (Hair Loss) | 0.4 | 0.4 | |
| Alzheimer's disease | 1 | 0.6 | 0.67 |
| Ankylosing spondylitis | 0.7 | 0.4 | 0.75 |
| Anorexia Nervosa | 0.4 | 0.3 | 0.33 |
| Antiphospholipid syndrome (APS) | 0.3 | -0.3 | |
| Asthma | 0.3 | 0.3 | 0 |
| Atherosclerosis | 0.3 | 0.3 | |
| Atrial fibrillation | 0.7 | 1 | -0.43 |
| Autism | 0.8 | 1.4 | -0.75 |
| benign prostatic hyperplasia | 0.3 | -0.3 | |
| Biofilm | 0.1 | 0.1 | |
| Bipolar Disorder | 1 | 1 | |
| Brain Trauma | 0.3 | -0.3 | |
| Cancer (General) | 0.2 | -0.2 | |
| Carcinoma | 1 | 0.7 | 0.43 |
| Celiac Disease | 0.3 | 1 | -2.33 |
| Cerebral Palsy | 0.3 | 0.3 | 0 |
| Chronic Fatigue Syndrome | 0.4 | 0.9 | -1.25 |
| Chronic Kidney Disease | 0.8 | 0.3 | 1.67 |
| Chronic Lyme | 0.3 | -0.3 | |
| Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | |
| Cognitive Function | 0.7 | 0.7 | |
| Colorectal Cancer | 1 | 0.3 | 2.33 |
| Constipation | 0.3 | 0.3 | |
| Coronary artery disease | 0.1 | 0.3 | -2 |
| COVID-19 | 0.8 | 0.5 | 0.6 |
| Crohn's Disease | 1.5 | 0.7 | 1.14 |
| Cushing's Syndrome (hypercortisolism) | 0.3 | -0.3 | |
| cystic fibrosis | 0.3 | -0.3 | |
| deep vein thrombosis | 0.3 | -0.3 | |
| Depression | 1.7 | 0.9 | 0.89 |
| Eczema | 0.1 | 0.1 | |
| Endometriosis | 0.7 | 0.7 | |
| Epilepsy | 0.3 | 0.7 | -1.33 |
| erectile dysfunction | 0.5 | 0.5 | |
| Fibromyalgia | 0.5 | 0.3 | 0.67 |
| Functional constipation / chronic idiopathic constipation | 0.7 | 0.7 | 0 |
| gallstone disease (gsd) | 0.5 | 0.5 | |
| Generalized anxiety disorder | 0.4 | 0.3 | 0.33 |
| Gout | 0.7 | 0.7 | |
| Graves' disease | 0.7 | 0.3 | 1.33 |
| Halitosis | 0.3 | 0.3 | |
| Hashimoto's thyroiditis | 0.3 | 0.6 | -1 |
| Heart Failure | 0.8 | 0.8 | |
| hemorrhagic stroke | 0.4 | 0.4 | |
| Hidradenitis Suppurativa | 0.6 | 0.6 | |
| hyperglycemia | 0.7 | -0.7 | |
| Hyperlipidemia (High Blood Fats) | 0.3 | 0.3 | |
| hypersomnia | 0.3 | -0.3 | |
| hypertension (High Blood Pressure | 0.7 | 0.6 | 0.17 |
| Hypoxia | 0.7 | 0.7 | |
| IgA nephropathy (IgAN) | 0.7 | 0.1 | 6 |
| Inflammatory Bowel Disease | 1 | 0.9 | 0.11 |
| Insomnia | 0.3 | 0.3 | 0 |
| Intelligence | 0.3 | 0.3 | |
| Intracranial aneurysms | 0.7 | 0.7 | |
| Irritable Bowel Syndrome | 0.4 | 0.7 | -0.75 |
| ischemic stroke | 0.7 | 0.3 | 1.33 |
| Liver Cirrhosis | 1 | 0.6 | 0.67 |
| Long COVID | 0.9 | 1 | -0.11 |
| Lung Cancer | 0.3 | 0.3 | |
| ME/CFS with IBS | 0.3 | -0.3 | |
| ME/CFS without IBS | 0.1 | 0.7 | -6 |
| Metabolic Syndrome | 1.4 | 1 | 0.4 |
| Mood Disorders | 1.6 | 0.9 | 0.78 |
| Multiple Sclerosis | 0.7 | 1.1 | -0.57 |
| neuropathic pain | 0.7 | -0.7 | |
| Neuropathy (all types) | 0.4 | -0.4 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.4 | 0.3 | 0.33 |
| NonCeliac Gluten Sensitivity | 0.3 | 0.3 | 0 |
| Obesity | 1.5 | 1 | 0.5 |
| obsessive-compulsive disorder | 0.7 | 0.4 | 0.75 |
| Osteoarthritis | 0.5 | 0.3 | 0.67 |
| Osteoporosis | 0.3 | 0.3 | 0 |
| Parkinson's Disease | 1 | 0.4 | 1.5 |
| Polycystic ovary syndrome | 1.2 | 0.6 | 1 |
| Premenstrual dysphoric disorder | 0.4 | -0.4 | |
| primary biliary cholangitis | 0 | 0 | |
| Primary sclerosing cholangitis | 0.7 | 0.9 | -0.29 |
| Psoriasis | 1.1 | -1.1 | |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.1 | 0.3 | 2.67 |
| Schizophrenia | 1 | 0.7 | 0.43 |
| scoliosis | 0.3 | -0.3 | |
| Sjögren syndrome | 0.4 | 0.7 | -0.75 |
| Sleep Apnea | 0.3 | -0.3 | |
| Slow gastric motility / Gastroparesis | 0.3 | 0.3 | |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
| Stress / posttraumatic stress disorder | 0.7 | 0.7 | 0 |
| Systemic Lupus Erythematosus | 1.1 | 1.1 | |
| Tourette syndrome | 0.3 | -0.3 | |
| Type 1 Diabetes | 0.6 | 0.3 | 1 |
| Type 2 Diabetes | 1.1 | 0.8 | 0.38 |
| Ulcerative colitis | 0.8 | 1 | -0.25 |
| Unhealthy Ageing | 0.7 | 0.4 | 0.75 |
| Vitiligo | 0.7 | 0.4 | 0.75 |
Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.
Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served. Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license. Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models. Inventions /Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions,
or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]
